The Parkinson’s Foundation announces centres for ‘under-served’ communities

News

Author: Joe McAweaneyPublished: 29 August 2019

Prep: Cook: Serves:

The Parkinson’s Foundation has announced the addition of three Centres of Excellence to its network of care facilities for people with Parkinson’s.

The centres, which are based in US states Colorado, Indiana and Pennsylvania, will primarily focus on ‘under-served’ (low income) communities which have less access to healthcare services – giving individuals from those areas priority in the application process.

The facilities will include specialised teams of neurologists, movement disorder specialists, mental health professionals and experts in Parkinson’s medication.

John L. Lehr, president of the Parkinson’s Foundation, said: “The newly designated Centers of Excellence join a network that is setting the highest standards of care for people with PD worldwide.

“We are proud to further our commitment to improving the quality of life for people with Parkinson’s and making a difference in under-served communities across the country.”

For more information on Parkinson’s and multidisciplinary care please visit the EPDA website.

To read more about this story click here.

Take part in a global Parkinson’s carers survey

Last Month

Next Month

Go Back

Share this story

Comments

Europe

My PD Journey: landmark Parkinson’s summit highlights urgent need for new composite scale

European coalition set to roll out new and simple composite scale

World’s first blood test for Parkinson’s may lead to earlier treatment

Potential laboratory test for Parkinson’s discovered

Advances

A future with fewer side effects for DBS-implanted patients

The future of DBS technology

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…

Students develop wearable device to track Parkinson’s tremors

A wearable device has been developed to monitor Parkinson’s tremors and their severity through the tracking of body movements. The device – Tremor Tracker – was created by two students, Julie Gaudin and Elizabeth Hummel, at Louisiana Tech University, US, as part of a design class project. The students designed an algorithm using data recorded from volunteer participants at Rock Steady, a boxing programme for people with Parkinson’s. They then applied the algorithm to a GENEActiv, a wrist-worn device that has been scientifically validated for clinical research. Hummel, co-creator of the Tremor Tracker, said: “Through supervised machine learning, the device predicts whether a patient’s tremors are parkinsonian or non-parkinsonian, as well as the severity of these tremors. A quantitative analysis of parkinsonian tremors provides a more detailed disease state.”

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

Reawakening dormant neurons could help reverse Parkinson’s motor symptoms, researchers in South Korea have found. While Parkinson’s is typically believed to be caused by neuronal death, a new study – published in ‘Current Biology’ journal – suggests that dormant neurons could be another cause. After completing an animal test – which treated the subjects with two compounds that block dopamine-producing neurons from becoming dormant – the researchers found these neurons to be “awakened”, allowing them to resume dopamine production. The researchers hope that this will lead to a disease-modifying treatment, especially for people in the early stages of Parkinson’s. Hoon Ryu, a senior author of the study and researcher at KIST Brain Science Institute, South Korea, said: “This research refutes the common belief that there is no disease-modifying treatment for Parkinson’s due to its basis on neuronal cell death.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

The Parkinson’s Foundation announces centres for ‘under-served’ communities

News

Author: Joe McAweaneyPublished: 29 August 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Europe

My PD Journey: landmark Parkinson’s summit highlights urgent need for new composite scale

Advances

World’s first blood test for Parkinson’s may lead to earlier treatment

sponsored article

Advances

A future with fewer side effects for DBS-implanted patients

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Students develop wearable device to track Parkinson’s tremors

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

{title}

Subscribe

The Parkinson’s Foundation announces centres for ‘under-served’ communities

News

Author: Joe McAweaneyPublished: 29 August 2019

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Europe

My PD Journey: landmark Parkinson’s summit highlights urgent need for new composite scale

Advances

World’s first blood test for Parkinson’s may lead to earlier treatment

sponsored article

Advances

A future with fewer side effects for DBS-implanted patients

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Students develop wearable device to track Parkinson’s tremors

Can awakening dormant neurons reverse Parkinson’s motor symptoms?

{title}

Subscribe

Sign in